Skip to main content

Advertisement

SpringerLink
Log in

Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Glucocorticoid-induced osteoporosis is a common but still relatively neglected problem, with a low level of awareness among primary and secondary care physicians. Fractures appear early after initiation of treatment, and effective prophylaxis requires primary prevention in those at high risk of fracture. Bisphosphonates are the treatment of choice, and calcium and vitamin D supplements are also indicated in the majority of individuals. Organized care programs together with the use of evidence-based guidelines have the potential to improve significantly the management of this serious complication of glucocorticoid therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids in the United Kingdom. QJM 2000, 93:105–111.

    Article  PubMed  Google Scholar 

  2. Hooyman JR, Melton LJ, Nelson AM, et al.: Fractures after rheum atoid arthritis. A population-based study. Arthritis Rheum 1984, 27:1353–1361.

    Article  PubMed  CAS  Google Scholar 

  3. van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993–1000.

    Article  PubMed  Google Scholar 

  4. Steinbuch M, Youket TE, Cohen S: Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004, 15:323–328.

    Article  PubMed  CAS  Google Scholar 

  5. Mazziotti G, Angeli A, Bilezikian JP, et al.: Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006, 17:144–149.

    Article  PubMed  CAS  Google Scholar 

  6. van Staa TP, Leufkens HG, Abenhaim L, et al.: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383–1389.

    Article  Google Scholar 

  7. van Staa TP, Dennison EM, Leufkens HG, Cooper C: Epidemiology of fractures in England and Wales. Bone 2001, 29:517–522.

    Article  PubMed  Google Scholar 

  8. Ip M, Lam K, Yam L, et al.: Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994, 105:1722–1727.

    PubMed  CAS  Google Scholar 

  9. Toogood JH, Baskerville JC, Markov AE, et al.: Bonemineral density and the risk of fracture in patients receiving long-term inhaled steroid-therapy for asthma. J Allergy Clin Immunol 1995, 96:157–166.

    Article  PubMed  CAS  Google Scholar 

  10. Wong CA, Walsh LJ, Smith CJ, et al.: Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 2000, 355:1399–1403.

    Article  PubMed  CAS  Google Scholar 

  11. van Staa T, Leufkens HG, Cooper C: Use of inhaled cortic osteroids and risk of fractures. J Bone Miner Res 2001, 16:581–588.

    Article  PubMed  Google Scholar 

  12. van Staa TP, Bishop N, Leufkens HG, Cooper C: Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 2004, 15:785–791.

    Article  PubMed  CAS  Google Scholar 

  13. Curtis JR, Westfall AO, Allison JJ, et al.: Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005, 52:2485–2494.

    Article  PubMed  Google Scholar 

  14. Feldstein AC, Elmer PJ, Nichols GA, Herson M: Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005, 16:2168–2174.

    Article  PubMed  CAS  Google Scholar 

  15. Blalock SJ, Norton LL, Patel RA, Dooley MA: Patient knowledge, beliefs, and behaviour concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2005, 53:732–739.

    Article  PubMed  Google Scholar 

  16. Newman ED, Matzko CK, Olenginski TP, et al.: Glucocorticoid-induced osteoporosis (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006, 17:1428–1434.

    Article  PubMed  CAS  Google Scholar 

  17. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002, 359:1929–1936.

    Article  PubMed  Google Scholar 

  18. Kanis JA, Johansson H, Oden A, et al.: A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19:893–899.

    Article  PubMed  Google Scholar 

  19. Homik J, Cranney A, Shea B, et al.: Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 2000, (2):CD001347.

  20. Adachi JD, Saag KG, Delmas PD, et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, doubleblind, placebo-controlled extension trial. Arthritis Rheum 2001, 44:202–211.

    Article  PubMed  CAS  Google Scholar 

  21. Adachi JD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. New Engl J Med 1997, 337:382–387.

    Article  PubMed  CAS  Google Scholar 

  22. Cohen S, Levy RM, Keller M, et al.: Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999, 42:2309–2318.

    Article  PubMed  CAS  Google Scholar 

  23. Herrala J, Puolijoki H, Impivaara O, et al.: Bone mineral density in asthmatic women on high dose inhaled beclomethasone dipropionate. Bone 1994, 15:621–624.

    Article  PubMed  CAS  Google Scholar 

  24. Reid IR, Heap SW, King AR, Ibbertson HK: Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet 1988, 2:1144.

    Article  PubMed  CAS  Google Scholar 

  25. Ringe JD, Dorst A, Faber H, et al.: Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003, 14:801–807.

    Article  PubMed  CAS  Google Scholar 

  26. Cranney A, Welch V, Adachi JD, et al.: Calcitonin for preventing and treating corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000, (2):CD001983.

  27. Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled trial. J Clin Invest 1998, 102:1627–1633.

    Article  PubMed  CAS  Google Scholar 

  28. Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944–951.

    Article  PubMed  CAS  Google Scholar 

  29. Homik J, Suarez-Almazor ME, Shea B, et al.: Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2002, (2):CD000952.

  30. Dykman R, Haralson KM, Gluck OS, et al.: Effect of oral 1,25-dhydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984, 27:1336–1343.

    Article  PubMed  CAS  Google Scholar 

  31. Sambrook P, Birmingham J, Kelly P, et al.: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. New Engl J Med 1993, 328:1747–1752.

    Article  PubMed  CAS  Google Scholar 

  32. Lambrinoudaki A, Chan DTM, Lau CS, et al.: Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy: a randomised, double-blind. placebo controlled study. J Rheumatol 2000, 27:1759–1765.

    PubMed  CAS  Google Scholar 

  33. Sambrook P, Henderson NK, Keogh A, et al.: Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000, 15:1818–1824.

    Article  PubMed  CAS  Google Scholar 

  34. Diamond T, McGuigan I, Schonell M, et al.: A 2 year open randomised controlled trial comparing calcitriol to cyclical etidronate for the treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 1997, 12:S311.

    Article  Google Scholar 

  35. Stempfle HU, Werner C, Echtler S, et al.: Prevention of osteoporosis after cardiac transplantation. Transplantation 1999, 68:523–530.

    Article  PubMed  CAS  Google Scholar 

  36. Reginster JY, Kuntz D, Verdickt W et al.: Prophylactic use of alfac alcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999, 9:75–81.

    Article  PubMed  CAS  Google Scholar 

  37. Lakatos P, Nagy Z, Kiss L, et al.: Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000, 59(Suppl 1):48–52.

    Article  PubMed  Google Scholar 

  38. Ringe JD, Cöster A, Meng T, et al.: Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 1999, 65:337–340.

    Article  PubMed  CAS  Google Scholar 

  39. Ringe JD, Faber H, Fahramand P, Schacht E: Alfac alcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis. J Rheumatol 2005, 76(Suppl):33–40.

    CAS  Google Scholar 

  40. Sambrook PN, Kotowitz M, Nash P, et al.: Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003, 18:919–924.

    Article  PubMed  CAS  Google Scholar 

  41. de Nijs RN, Jacobs JW, Lems WF, et al.: Alendronate or alfac alcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006, 355:675–684.

    Article  PubMed  Google Scholar 

  42. American College of Rheumatology adhoc Committee on Glucocorticoid-induced Osteoporosis: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001, 44:1496–1503.

  43. Guidelines Working Group for the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians 2002: Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians; 2002.

    Google Scholar 

  44. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002, 167(10 Suppl):S1–34.

    PubMed  Google Scholar 

  45. Nawata H, Soen S, Takayanagi R, et al.: Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society of Bone and Mineral Research. J Bone Miner Metab 2005, 23:105–109.

    Article  PubMed  Google Scholar 

  46. Geusens PP, Lems WF, Verhaar HJ, et al.: Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 2006, 12:539–548.

    Article  PubMed  Google Scholar 

  47. Devogelaer JP, Goemaere S, Boonen S, et al.: Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006, 17:8–19.

    Article  PubMed  CAS  Google Scholar 

  48. Pennisi P, Trombetti A, Rizzoli R: Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006, 443:39–47.

    Article  PubMed  Google Scholar 

  49. Curtis JR, Westfall AO, Allison JJ, et al.: Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006, 17:1268–1274.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Cambridge School of Clinical Medicine, and Addenbrooke’s Hospital, Box 157, Cambridge, CB2 2QQ, UK

    Juliet E. Compston MD, FRCPath, FRCP, FMedSci

Authors
  1. Juliet E. Compston MD, FRCPath, FRCP, FMedSci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juliet E. Compston MD, FRCPath, FRCP, FMedSci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Compston, J.E. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 9, 78–84 (2007). https://doi.org/10.1007/s11926-007-0026-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0026-x

Keywords

Search

Navigation